Abstract
Brand-name vancomycin consistently outperforms generic—supposedly, equivalent—forms of this storied antibiotic, according to Omar Vesga, of the University of Antioquia Medical School in Medellin, Colombia, and his collaborators. “Now we know that therapeutic equivalence of generic vancomycin cannot be assumed from pharmaceutical equivalence, or from so-called bioequivalence,” he says. These research findings appear in the August Antimicrobial Agents and Chemotherapy (54:3271–3279).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
